World Health Organization Tag

  • All
  • Advocacy Hub
  • Advocacy Update
  • Blog Posts
  • GHC Announcements
  • News Center
  • Statement
A Devex Conversation With Dr. Tedros Adhanom Ghebreyesus

Organized by Devex 

A Devex Conversation With Dr. Tedros Adhanom Ghebreyesus
January 25
9:00 AM – 10:00 AM EST
World Economic Forum Annual Meeting
Davos, Switzerland

MORE INFORMATION AND REGISTRATION

(This event will be live-streamed)

Devex invites you to join for a conversation between the World Health Organization’s Director-General Dr. Tedros Adhanom Ghebreyesus and Devex President & Editor-in-Chief Raj Kumar, as they discuss the Director-General’s stated priorities for the WHO live from the World Economic Forum Annual Meeting in Davos, Switzerland.

Hear from Dr. Tedros directly as we discuss his stated priorities for the World Health Organization, including universal health coverage and recognition of health as a basic human right, as well as pressing issues such as the global health community’s preparedness for growing urbanization and population longevity.

0
142nd WHO Executive Board Session Briefing

Organized by

142nd WHO Executive Board Session Briefing
January 17
1:30 PM – 2:30 PM EST
Webinar

REGISTRATION

SUBMIT YOUR QUESTIONS FOR THE Q/A SESSION

(Deadline for submission is January 16)

Join GHC for a webinar briefing to gather insights regarding the 142nd WHO Executive Board (EB) session, which opens in Geneva on January 22. The webinar will feature remarks from GHC members and partners and will address critical EB discussions on WHO’s leadership priorities, including the draft thirteenth general programme of work 2019–2023, TB, and NCDs. U.S. government staff have been invited to attend the briefing. Remarks will be followed by a Q&A/Discussion with participants. GHC is now accepting questions from participants ahead of the webinar for the Q&A session. Please complete this form by no later than January 16.

Special guests include:

1) Garret Grigsby, Director of the Office of Global Affairs, U.S. Department of Health & Human Services

2) Jenifer Healy, Chief of Staff, Office of Global Affairs, U.S. Department of Health & Human Services

 

1
Women on the Move: Migration, Care Work and Health

Organized by Global Health Centre at the Graduate Institute and World Health Organization (WHO)

November 21
6:30 PM – 7:30 PM
Auditorium 2, Maison de la Paix
Geneva, Switzerland

MORE INFORMATION

REGISTRATION

 

Photo Courtesy: Global Health Centre at the Graduate Institute

 

Migrant women care workers act as a cushion for states lacking adequate public provision for long-term care, particularly for older people and the sick. Together with the rising demographic dependency ratios and female labor force participation, aging in late industrial and middle-income economies is leading to care deficits worldwide. WHO has produced a new analytical report on this population group, collating evidence across sectors and covering countries that send and receive large numbers of migrant women working in the care sector.

This event will present the report and its findings and key messages on the state of evidence on this population group, the work they do and the lives they lead, the emergence of global care chains and transnational families, as well as the legal and policy frameworks which affect their lives, and what needs to change.

The high-level panelists include:

1) Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
2) Ambassador Laura Thompson,  Deputy Director General, International Organization for Migration
3) Kate Gilmore, United Nations Deputy High Commissioner for Human Rights
4) Dr Princess Nothemba Simelela, Assistant Director General, Family, Women’s and Children’s Health Cluster, World Health Organization
5) Bernhard Schwartländer, Chef de Cabinet, World Health Organization
6) Dr Alan Ludowyke, Director, International Health, Ministry of Health, Nutrition and Indigenous Medicine, Sri Lanka
7) Dr Ilona Kickbusch, Director, Global Health Centre, Graduate Institute
8) Dr Veronica Magar, Gender, Equity and Rights Team Leader, World Health Organization

13
Webinar on HIV Drug Resistance (HIVDR)

Organized by

July 28
9.30 AM – 11.00 AM EDT
Webinar

Briefing on new WHO reports profiled at the 9th IAS Conference in Paris
2017 HIVDR Report 2017
WHO Guidelines on the public health response to pretreatment HIVDR
Global Action Plan on HIVDR, 2017-2021
View these reports

Webinar Details:

To help our planning, please email sunderlandd@who.int to indicate if you plan to come.

Join Web-Ex Meeting:
https://who-meeting.webex.com/who-meeting/j.php?MTID=m87474c2fedb93ed421d9e96f00c736be
Access Code: 842 806 065

Join from a video system or application:
Dial 842806065@who-meeting.webex.com.

Join by phone:
UK Toll: +44-203-478-5289
USA/Canada Toll: +1 631-267-4890

More global call-in numbers

 

Recognizing the need for a coordinated global effort to prevent HIVDR from undermining the attainment of global targets and to provide the most effective treatment to people living with HIV, WHO has developed the 2017 HIVDR ReportWHO Guidelines on the public health response to pretreatment HIVDR, and Global Action Plan on HIVDR, 2017-2021.

Silvia Bertagnolio leads WHO’s work on HIVDR and will make a presentation on the reports.  She will be joined by Anton Ofield-Kerr, Director of Equal International, which supported the development of the Global Action Plan.  The webinar will provide an opportunity to discuss HIVDR and consider feedback from the IAS conference, as well as consider inputs from Global Health Council members.

The HIV drug resistance report 2017 presents recent HIVDR data from a nationally representative survey of pretreatment and acquired HIVDR. Results are contextualized by systematic reviews of the published literature assessing HIVDR in adults and children. The report informs prevention activities and the public health response to HIVDR.

The Guidelines on the public health response to pretreatment HIV drug resistance answer the following questions:

1.  At what prevalence of HIVDR amongst people starting ART should a public health intervention be triggered?

2.  What is the appropriate response(s) in countries with elevated levels of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance?

The Global Action Plan on HIVDR, 2017-2021, developed in collaboration with partners and stakeholders, provides a five-year framework for action centered on five strategic objectives.  The framework outlines key actions for all partners involved in the global response to HIVDR, and links to indicators to track implementation of the plan.

16
WHO says “no thanks” to the private sector

This blog was written by Matthew Robinson and cross-posted from the GHTC Coalition Blog

There’s an old adage about political negotiating: “You need to be in the room when things are happening if you want to have an impact.” At its recent meeting, the World Health Organization (WHO) Executive Board (EB) discussed precisely who would be allowed in the room in the future under the proposed new Framework for Engagement with Non-State Actors (FENSA), which, if passed by the World Health Assembly (WHA), would set strict new rules and processes for WHO to follow in engaging with non-state actors (NSA)—including nongovernmental organizations (NGOs), civil society organizations (CSOs), the private sector, and philanthropic foundations. These new policies impact everything from who is allowed to participate in governance meetings to the ways WHO can collaborate with local NGOs. To provide some context for the proposed changes, below is an overview of the current rules, the proposed new regulations, and some of the implications of particular concern for the global health research and development (R&D) world.

Current rules governing engagement with NSAs

The current rules governing WHO’s collaboration with NSAs derive from “Principles Governing Relations Between the World Health Organization and Nongovernmental Organizations.” The Principles recognize three levels of relations between WHO and NSAs: informal, working, and official. Informal relations consist of “…exchanges of information and reciprocal participation in technical meetings” and are designed to build a platform of shared priorities. They can continue on an ad-hoc basis for as long as necessary without any written agreement.

If the relationship elevates to the level of specific joint programming and activities, WHO and the NSA can enter into a 2-year period of working relations. The two organizations exchange formal letters of commitment and agree to evaluate the outcome of the collaboration at the end of the joint activities. These types of collaboration do not require any decisions by the EB and can occur with WHO Secretariat staff approval; they do not grant any formal participation rights at the EB or WHA.

To receive formal recognition and participation rights at the EB and WHA, an NSA must complete a successful period of working relations and submit an application to the EB. If admitted into formal relations, the NSA’s relationship with WHO is then subject to review every three years. If the application is rejected, the NSA cannot reapply until it has completed another period of working relations.

Proposed new regulations

The new proposed FENSA rules take a far different approach. Rather than recognizing three different categories of relations, it features only two: official relations and “engagement.” Unlike the current regulations, however, it does specify different rules of engagement depending on the type of NSA; NGOs/nonprofits are treated differently than philanthropic foundations, which are treated differently than academic institutions, which are in turn treated differently than the private sector. Of particular note for the R&D community, private-sector entities would be barred from official relations, as would any entities not “at arm’s length” from commercial sponsors or members. This could be interpreted to include some product development partnerships.

Under FENSA, WHO would be required to create a publicly-available online register of every NSA it engages with at the global, regional, or country level. A pilot version of this register is currently available here. Each NSA that wished to engage with WHO would be required to populate all of the information shown in the link above as well as a to-be-determined section detailing the precise nature and funding of the engagement. For the purpose of registration requirements, engagements are defined as: participation in meetings, donation of resources, information/evidence sharing, advocacy efforts, and technical or programmatic collaboration. Essentially, as currently written, this category requires registration for almost any type of collaboration.

When an organization proposes engagement(s), WHO Secretariat staff would be required to review both the organization’s information and the proposed activity in the register, as well as conduct a full due diligence assessment on risk management and potential conflicts of interest. Only after these processes have completed would the activity move forward. The staff burden of these processes is hard to overstate; the European WHO region had over 5,000 individual engagements with over 1,500 NSAs in 2014 alone.

As shocking as it sounds, all of the above scrutiny would be required for simple “engagement,” not for official relations. In order to guarantee the right of representation at EB and WHA meetings, an organization would still need to submit a separate application with even more extensive documentation.

Implications for the health R&D community

Ultimately, FENSA, if implemented as it currently stands, does not seem likely to fix any problems, while it would likely create additional hurdles for the R&D community by:

1)  Greatly hindering the ability of WHO to collaborate with outside organizations by imposing a burdensome registration and review process for every type of engagement (no matter how small or informal).
2)  Potentially disenfranchising significant sectors of the global health R&D community by imposing stricter requirements that might redefine some product development partnerships as private-sector organizations that are not entitled to representation.

The WHO working group revising FENSA will meet again in early April to attempt to reach an agreement so that they can present a consensus resolution to the WHA in May. We will be following the process very closely, and will provide further updates on this blog as they happen.

Matthew Robinson is GHTC’s Policy & Advocacy Officer.